Drug intelligence / Profile preview

ACT400

Development stage: Preclinical
Lead developer: Xiamen Tebao Biological Engineering

Overview

ACT400 is an investigational therapeutic candidate currently in the preclinical stage of development by Xiamen Amoytop Biotech. It is being developed for the treatment of chronic hepatitis B (CHB) as part of the company's immunology-focused pipeline. While specific molecular details, such as its target and modality, have not been publicly disclosed, ACT400 is part of a broader portfolio of innovative assets (including ACT201 and ACT560) aimed at achieving a functional cure for hepatitis B virus (HBV) infection by modulating the host immune response.

Beyond the preview

Go deeper on ACT400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACT400.

Explore the full profile